Skip to main content
Premium Trial:

Request an Annual Quote

Lion Bioscience Licenses SRS to AstraZeneca

NEW YORK, February 12 -- Lion Bioscience has licensed its SRS biotechnology platform to AstraZeneca, the company said today.


By taking a global perpetual license, the pharmaceutical company will have access to Lion's SRS integration software as well as the SRS Relational module.


Financial terms of the deal were not disclosed.


Since December, Lion has rolled out a series of SRS licensing announcements, including deals with Italy's Siena Biotech, Eli Lilly and Company, Johnson & Johnson Pharmaceutical Research and Development, and Cellzome.


The Heidelberg, Germany-based bioinformatics company restructured last year, cutting nearly 200 jobs and closing its drug discovery operations.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.